SOURCE: MDRNA, Inc.

MDRNA, Inc.

February 08, 2010 07:30 ET

MDRNA, Inc. Receives Compliance Extension From NASDAQ

BOTHELL, WA--(Marketwire - February 8, 2010) - MDRNA, Inc. (NASDAQ: MRNA) announced that it received a letter on February 5, 2010 from The NASDAQ Stock Market, Inc. notifying the Company that, as a result of Securities and Exchanges Commission (SEC) approved changes to NASDAQ Listing Rules, MDRNA now has a grace period of 180 days from its initial notice of non-compliance in which to regain compliance with the $50 million minimum Market Value of Listed Securities (MVLS) for continued listing on The NASDAQ Global Market as set forth in NASDAQ Marketplace Rule 5450(b)(3)(A). The Company's grace period has been extended until May 5, 2010 in order to regain compliance, which can be achieved if the Company's MVLS closes at $50 million or more for a minimum of ten consecutive business days during this time. MDRNA will continue to be listed on the NASDAQ Global Market during this period.

About MDRNA, Inc.

MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Our goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Over the past decade, we have developed substantial capabilities in molecular biology, cellular biology, lipid chemistry, peptide chemistry, pharmacology and bioinformatics, which we are applying to a wide range of RNAi technologies and delivery approaches. These capabilities plus the in-licensing of key RNAi-related intellectual property have rapidly enabled us to become a leading RNAi-based therapeutics company with a pre-clinical pipeline in oncology. Through our capabilities, expertise and know-how, we are incorporating multiple RNAi technologies as well as peptide- and lipid-based delivery approaches into a single integrated drug discovery platform that will be the engine for our clinical pipeline as well as a versatile platform for establishing broad therapeutic partnerships with biotechnology and pharmaceutical companies. We are also investing in new technologies that we expect to lead to safer and more effective RNAi-based therapeutics while aggressively building upon our broad and extensive intellectual property estate. By combining broad expertise in siRNA science with proven delivery platforms and a strong IP position, MDRNA is well positioned as a leading RNAi-based drug discovery and development company. Additional information about MDRNA, Inc. is available at http://www.mdrnainc.com.

MDRNA Forward-Looking Statements

Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of MDRNA to obtain additional funding; (ii) the ability of MDRNA to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of MDRNA and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of MDRNA and/or a partner to obtain required governmental approvals; and (v) the ability of MDRNA and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in MDRNA's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. MDRNA assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Contact Information